Home World News No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with... World News No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - August 13, 2026 155 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENDURANCE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Should People With Cancer Be Tested for Hepatitis B? July 27, 2020 FDA Approves Cabozantinib for Differentiated Thyroid Cancer September 30, 2021 How Do Black People with Cancer View Clinical Research? November 15, 2024 ‘From virtual reality tumours to cutting-edge treatments’: what to expect from... May 23, 2022 Load more HOT NEWS Sister Is There To Comfort Her Little Brother As He Battles... A Safer, Better Treatment Option for Some Younger Women with Breast... ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ Large Study Confirms that HPV Vaccine Prevents Cervical Cancer
